A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs
BackgroundWe developed a new predictive staging system to explore the heterogeneity of survival in newly diagnosed multiple myeloma (NDMM) patients in the real world.MethodsIn this retrospective study, we evaluated the predictive value of cytogenetic abnormal and clinical data in 375 patients with N...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-10-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1473034/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850213670412353536 |
|---|---|
| author | Ye Li Ye Li Junru Liu Jingjing Deng Yuan Jian Zhiyao Zhang Huixing Zhou Juan Li Wenming Chen |
| author_facet | Ye Li Ye Li Junru Liu Jingjing Deng Yuan Jian Zhiyao Zhang Huixing Zhou Juan Li Wenming Chen |
| author_sort | Ye Li |
| collection | DOAJ |
| description | BackgroundWe developed a new predictive staging system to explore the heterogeneity of survival in newly diagnosed multiple myeloma (NDMM) patients in the real world.MethodsIn this retrospective study, we evaluated the predictive value of cytogenetic abnormal and clinical data in 375 patients with NDMM at our center. Established a weighted MM prognostic scoring system risk model and validated its predicted PFS and OS by external cohort.ResultsElevated lactate dehydrogenase levels (1 point), international staging system stage II/III (1 point), 1q21+ ≥ 52.75% (0.5 point), del (17p) ≥ 3.5% (0.5 point), and t (14;16) ≥ 35.25% (1 point) had independent prognostic significance. Patients were further divided into three risk groups: low (I) (score 0–0.5, 16.5%), intermediate (II) (score 1, 46.7%), and high (III) (score 1.5–3, 36.8%). In the training cohort, the 3-year PFS was 79.5% vs. 65.3% vs. 40.3% (p < 0.001), and the 3-year OS was 87.7% vs.70.1% vs. 55% (p < 0.001) for the three risk groups. In the external validation cohort, the 3-year PFS was 85.5% vs.61.2% vs. 43.1% (p < 0.001) and the 3-year OS was 91.4% vs.83.5% vs. 56.9% (p < 0.001) for the three risk groups.ConclusionThe risk stratification of this model shows good discrimination and calibration, and its application in clinical practice can improve the risk assessment of patients with NDMM and guide personalized treatment strategies. |
| format | Article |
| id | doaj-art-c3bd0f03e7ec4e4d8602356e2c8fdb2f |
| institution | OA Journals |
| issn | 2296-858X |
| language | English |
| publishDate | 2024-10-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-c3bd0f03e7ec4e4d8602356e2c8fdb2f2025-08-20T02:09:05ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2024-10-011110.3389/fmed.2024.14730341473034A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugsYe Li0Ye Li1Junru Liu2Jingjing Deng3Yuan Jian4Zhiyao Zhang5Huixing Zhou6Juan Li7Wenming Chen8Department of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, ChinaPeking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for Hematological Diseases, Beijing, ChinaDepartment of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, ChinaDepartment of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, ChinaDepartment of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, ChinaDepartment of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, ChinaDepartment of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaDepartment of Hematology, Myeloma Research Center of Beijing, Beijing Chaoyang Hospital, Capital Medical University, Beijing, ChinaBackgroundWe developed a new predictive staging system to explore the heterogeneity of survival in newly diagnosed multiple myeloma (NDMM) patients in the real world.MethodsIn this retrospective study, we evaluated the predictive value of cytogenetic abnormal and clinical data in 375 patients with NDMM at our center. Established a weighted MM prognostic scoring system risk model and validated its predicted PFS and OS by external cohort.ResultsElevated lactate dehydrogenase levels (1 point), international staging system stage II/III (1 point), 1q21+ ≥ 52.75% (0.5 point), del (17p) ≥ 3.5% (0.5 point), and t (14;16) ≥ 35.25% (1 point) had independent prognostic significance. Patients were further divided into three risk groups: low (I) (score 0–0.5, 16.5%), intermediate (II) (score 1, 46.7%), and high (III) (score 1.5–3, 36.8%). In the training cohort, the 3-year PFS was 79.5% vs. 65.3% vs. 40.3% (p < 0.001), and the 3-year OS was 87.7% vs.70.1% vs. 55% (p < 0.001) for the three risk groups. In the external validation cohort, the 3-year PFS was 85.5% vs.61.2% vs. 43.1% (p < 0.001) and the 3-year OS was 91.4% vs.83.5% vs. 56.9% (p < 0.001) for the three risk groups.ConclusionThe risk stratification of this model shows good discrimination and calibration, and its application in clinical practice can improve the risk assessment of patients with NDMM and guide personalized treatment strategies.https://www.frontiersin.org/articles/10.3389/fmed.2024.1473034/fullmultiple myelomacytogenetic abnormalFISHcutoffprognosis |
| spellingShingle | Ye Li Ye Li Junru Liu Jingjing Deng Yuan Jian Zhiyao Zhang Huixing Zhou Juan Li Wenming Chen A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs Frontiers in Medicine multiple myeloma cytogenetic abnormal FISH cutoff prognosis |
| title | A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs |
| title_full | A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs |
| title_fullStr | A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs |
| title_full_unstemmed | A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs |
| title_short | A new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs |
| title_sort | new prognostic scoring system for newly diagnosed multiple myeloma in the era of new drugs |
| topic | multiple myeloma cytogenetic abnormal FISH cutoff prognosis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1473034/full |
| work_keys_str_mv | AT yeli anewprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT yeli anewprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT junruliu anewprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT jingjingdeng anewprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT yuanjian anewprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT zhiyaozhang anewprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT huixingzhou anewprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT juanli anewprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT wenmingchen anewprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT yeli newprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT yeli newprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT junruliu newprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT jingjingdeng newprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT yuanjian newprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT zhiyaozhang newprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT huixingzhou newprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT juanli newprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs AT wenmingchen newprognosticscoringsystemfornewlydiagnosedmultiplemyelomaintheeraofnewdrugs |